

## PRIOR AUTHORIZATION REQUEST FORM EOC ID:

## Tremfya (guselkumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Dationt Name:	Prescriber Name:	
Patient Name:	Supervising Physicia	II.
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or informatio following qu	n for this patient that ma	ay support approval. Please answer the
Q1. What diagnosis is this drug being prescribed for (pick	one)?	
☐ Plaque Psoriasis ☐ Other	,	
<u> </u>		
Q2. Please provide ICD code for diagnosis.		
Q3. Please indicate location of administration.		
☐ Home		
☐ Long Term Care (LTC) facility		
☐ Physician office (drug from office stock)		
☐ Physician office (drug from pharmacy with a prescripti	ion)	
Q4. Is the prescriber a Dermatologist?		
☐ Yes ☐ No		
Q5. Does the patient have moderate to severe plaque pso (BSA)?	oriasis affecting greater	than 10% of body surface area
☐ Yes ☐ No		
Q6. Does the patient have moderate to severe plaque pso	oriasis affecting crucial	body areas such as hands, feet, face,



## PRIOR AUTHORIZATION REQUEST FORM EOC ID: Tremfya (guselkumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:	
Patient Name:	Supervising Physician:	
or genitals?		
☐ Yes ☐ No		
Q7. Has the patient failed at least TWO TOPICAL treatme analogues, Vitamin D analogue/corticosteroid combination  Yes  No	•	
Q8. Does the patient have failure of an adequate trial, into PUVA)?	lerance, or contraindication to phototherapy (UVB or	
☐ Yes ☐ No		
Q9. Does the patient have failure of an adequate trial of one or intolerance, or contraindication to methotrexate, cyclosporine, acitretin, leflunomide, sulfasalazine, and tacrolimus?		
☐ Yes ☐ No		
Q10. Please select all of the following agents that the patie contraindication to:    Humira	ent has failure of an adequate trial, intolerance, or	
Q11. Additional comments		
Prescriber Signature	Date	



## PRIOR AUTHORIZATION REQUEST FORM EOC ID: Tremfya (guselkumab)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

	Prescriber Name:	
Patient Name:	Supervising Physician:	
From the different. Do should be this has not defined as the standard of the standard or the s		

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document